To assess how key effectors in the adaptive immune system contribute to the protective anti-tumor response triggered by OpdA, we used genetically modified animals lacking IFN-γ and performed in vivo depletion of CD4+ and CD8+ T lymphocytes using specific monoclonal antibodies. The gene discussed is IFNG; the disease is neoplasm.